注意力不足過動症的治療
參考文獻

↑  Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, Arnold LE. . BMC Med. 2012-09-04, 10: 99. PMC 3520745 . PMID 22947230. doi:10.1186/1741-7015-10-99.
1 2 3  Wolraich, M.; Brown, L.; Wolraich, RT.; Brown, G.; Brown, M.; Dupaul, HM.; Earls, TG.; Feldman, B.;  et al. Steering Committee on Quality Improvement Management. . Pediatrics. November 2011, 128 (5): 1007–22. PMC 4500647 . PMID 22003063. doi:10.1542/peds.2011-2654. 5b: For elementary school-aged children (6–11 years of age), ...
Action statement 5c: For adolescents (12–18 years of age), ...
Similar to the recommendations from the previous guideline, stimulant medications are highly effective for most children in reducing core symptoms of ADHD.44 One selective norepinephrine-reuptake inhibitor (atomoxetine45,46) and 2 selective α2-adrenergic agonists (extended-release guanfacine47,48 and extended-release clonidine49) have also demonstrated efficacy in reducing core symptoms. Because norepinephrine-reuptake inhibitors and α2-adrenergic agonists ...  Compared with stimulant medications that have an effect size [effect size = (treatment mean — control mean)/control SD] of approximately 1.0,50 the effects of the nonstimulants are slightly weaker; atomoxetine has an effect size of approximately 0.7, and extended-release guanfacine and extended-release clonidine also have effect sizes of approximately 0.7.
1 2  . UpToDate.   [2018-03-17]. （原始内容存档于2019-06-08）. For school-aged children (≥6 years) and adolescents with ADHD, ...
1 2  Stein MA. . American Journal of Managed Care. July 2004, 10 (4 Suppl): S89–98  [2019-12-21]. PMID 15352535. （原始内容存档于2020-03-08）.
1 2  Christman AK, Fermo JD, Markowitz JS. . Pharmacotherapy. August 2004, 24 (8): 1020–36. PMID 15338851. doi:10.1592/phco.24.11.1020.36146.
1 2  Hazell, P. . Expert Opinion on Pharmacotherapy. October 2005, 6 (12): 1989–98. PMID 16197353. doi:10.1517/14656566.6.12.1989.
↑  Waxmonsky, James. . Current Opinion in Pediatrics. October 2003, 15 (5): 476–482. PMID 14508296. doi:10.1097/00008480-200310000-00006.
1 2 3 4 5 6  American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. . Pediatrics. October 2001, 108 (4): 1033–44. PMID 11581465. doi:10.1542/peds.108.4.1033.
↑  Kazdin, Alan E. Parent management training : treatment for oppositional, aggressive, and antisocial behavior in children and adolescents. Oxford University Press, 2005
↑  Melby-Lervåg M, Hulme C. . Dev Psychol. February 2013, 49 (2): 270–91. CiteSeerX 10.1.1.281.7759 . PMID 22612437. doi:10.1037/a0028228.
↑  Sonuga-Barke, E; Brandeis, D; Holtmann, M; Cortese, S. . Child and Adolescent Psychiatric Clinics of North America. October 2014, 23 (4): 807–824. PMID 25220088. doi:10.1016/j.chc.2014.05.009.
↑  Mayes R, Bagwell C, Erkulwater J. . Harvard Review of Psychiatry. 2008, 16 (3): 151–66. PMID 18569037. doi:10.1080/10673220802167782.
↑  Parker J, Wales G, Chalhoub N, Harpin V. . Psychology Research and Behavior Management. 2013-09, 6: 87–99. PMC 3785407 . PMID 24082796. doi:10.2147/PRBM.S49114. Results suggest there is moderate-to-high-level evidence that combined pharmacological and behavioral interventions, and pharmacological interventions alone can be effective in managing the core ADHD symptoms and academic performance at 14 months. However, the effect size may decrease beyond this period. ... Only one paper examining outcomes beyond 36 months met the review criteria. ... There is high level evidence suggesting that pharmacological treatment can have a major beneficial effect on the core symptoms of ADHD (hyperactivity, inattention, and impulsivity) in approximately 80% of cases compared with placebo controls, in the short term.22
↑  Sulzer D, Sonders MS, Poulsen NW, Galli A. . Progress in Neurobiology. 2005-04, 75 (6): 406–33. PMID 15955613. doi:10.1016/j.pneurobio.2005.04.003.
↑  Howland RH. . Journal of Psychosocial Nursing and Mental Health Services. 2008-08, 46 (8): 19–22. PMID 18777964. doi:10.3928/02793695-20080801-05.
↑  National Toxicology Program. . NTP Cerhr Mon. 2005-07, (16): vii–III1. PMID 16130031.
↑  Malenka RC, Nestler EJ, Hyman SE. . Sydor A, Brown RY  (编).  2nd. New York: McGraw-Hill Medical. 2009: 266, 318–323. ISBN 978-0-07-148127-4.
↑  Malenka RC, Nestler EJ, Hyman SE. . Sydor A, Brown RY  (编).  2nd. New York: McGraw-Hill Medical. 2009: 148, 154–157. ISBN 978-0-07-148127-4.
↑  King, S; Griffin, S; Hodges, Z. . Health Technology Assessment. 2006-07, 10 (23): iii–iv, xiii–146. PMID 16796929. doi:10.3310/hta10230. （原始内容存档于2009-08-15）.
↑  Murphy, Kevin R; Barkley, Russell A.  Third. New York: Guilford Press. 2005. ISBN 978-1-59385-227-6.
↑  Stern HP, Stern TP. . South. Med. J. 2002-09, 95 (9): 985–91. PMID 12356139. doi:10.1097/00007611-200209000-00011.
↑  Lerner M, Wigal T. . Pediatric Annals. 2008-01, 37 (1): 37–45. PMID 18240852. doi:10.3928/00904481-20080101-11.
↑  . Janssen Pharmaceuticals, Inc. 2014-07-15  [2014-09-06]. （原始内容存档于2014-11-26）.
1 2 3  Jensen; Garcia, JA; Glied, S; Crowe, M; Foster, M; Schlander, M; Hinshaw, S; Vitiello, B; Arnold, LE. . American Journal of Psychiatry. 2005, 162 (9): 1628–1636. PMID 16135621. doi:10.1176/appi.ajp.162.9.1628. hdl:1811/51178.
↑  Weiss MD, Gadow K, Wasdell MB. . J Clin Psychiatry. 2006,. 67 Suppl 8: 38–45. PMID 16961429.
↑  Ruiz-Goikoetxea, Maite; Cortese, Samuele; Aznarez-Sanado, Maite; Magallón, Sara; Alvarez Zallo, Noelia; Luis, Elkin O.; de Castro-Manglano, Pilar; Soutullo, Cesar; Arrondo, Gonzalo. . Neuroscience & Biobehavioral Reviews. 2018, 84: 63–71. ISSN 0149-7634. PMID 29162520. doi:10.1016/j.neubiorev.2017.11.007.
↑  Dalsgaard, Søren; Leckman, James F.; Mortensen, Preben Bo; Nielsen, Helena Skyt; Simonsen, Marianne. . The Lancet. Psychiatry. 2015-08-01, 2 (8): 702–709. ISSN 2215-0374. PMID 26249301. doi:10.1016/S2215-0366(15)00271-0.
1 2 3  Arnold LE. . Journal of Attention Disorders. 2000, 3 (4): 200–211. doi:10.1177/108705470000300403 .
↑  Rapoport JL, Inoff-Germain G. . J Atten Disord. 2002,. 6 Suppl 1: S57–60. PMID 12685519. doi:10.1177/070674370200601s07.
↑  Dusan Kolar; Amanda Keller; Maria Golfinopoulos; Lucy Cumyn; Cassidy Syer; Lily Hechtman. . Neuropsychiatr Dis Treat. 2008-02, 4 (1): 107–121. PMC 2515906 . PMID 18728812. doi:10.2147/ndt.s1747.
↑  Spencer TJ. . CNS Spectr. 2007-04, 12 (4(supplement 6)): 8–11. PMID 17715564. doi:10.1017/S1092852900026018.
↑  Rostain, Anthony L. . Postgraduate Medicine. 2008-09, 120 (3): 27–38  [2022-01-08]. PMID 18824823. doi:10.3810/pgm.2008.09.1905. （原始内容存档于2009-07-19）.
↑  Spencer, Thomas; Biederman, Joseph; Wilens, Timothy. . Psychiatric Clinics of North America. 2004-06, 27 (2): 361–372  [2022-01-08]. PMID 15064002. doi:10.1016/j.psc.2003.12.002. （原始内容存档于2016-10-24）.
↑  Higgins ES. . J Fam Pract. 1999-01, 48 (1): 15–20. PMID 9934377.
↑  Verbeeck W, Tuinier S, Bekkering GE. . Adv Ther. 2009-02, 26 (2): 170–184. PMID 19238340. doi:10.1007/s12325-009-0008-7.
↑  . UpToDate.   [2018-07-26]. （原始内容存档于2018-07-26）.
↑  . DailyMed. 2019-05-16  [2019-09-03]. （原始内容存档于2017-03-20）.
1 2 3  Huybrechts, Krista F.; Bröms, Gabriella; Christensen, Lotte Brix; Einarsdóttir, Kristjana; Engeland, Anders; Furu, Kari; Gissler, Mika; Hernandez-Diaz, Sonia; Karlsson, Pär; Karlstad, Øystein; Kieler, Helle; Lahesmaa-Korpinen, Anna-Maria; Mogun, Helen; Nørgaard, Mette; Reutfors, Johan; Sørensen, Henrik Toft; Zoega, Helga; Bateman, Brian T. . JAMA psychiatry (American Medical Association (AMA)). 2018-02-01, 75 (2): 167. ISSN 2168-622X. PMC 5838573 . PMID 29238795. doi:10.1001/jamapsychiatry.2017.3644.
1 2 3  . UpToDate.   [2018-09-09]. （原始内容存档于2018-12-25）. Proton Pump Inhibitors: May increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. Risk C: Monitor therapy
1 2 3 4  . Accredited Continuing Education Courses for Mental Health and Psychology Counselors and CME Conferences.   [2018-08-19]. （原始内容存档于2018-02-03）.
1 2 3 4  Ben Amor, L; Sikirica, V; Cloutier, M; Lachaine, J; Guerin, A; Carter, V; Hodgkins, P; van Stralen, J. . Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent. 2014, 23 (3): 157–66. ISSN 1719-8429. PMC 4197516 . PMID 25320609.
1 2 3 4  . UpToDate.   [2018-09-09]. （原始内容存档于2018-12-25）.
↑  . DailyMed. 2019-01-31  [2019-09-03]. （原始内容存档于2017-03-26）.
↑  . 衛生福利部中央健康保險署. 衛生福利部中央健康保險署. 2017-02-06  [2017-04-10]. （原始内容存档于2017-04-10）.
↑   (PDF). 衛生福利部中央健康保險署. 衛生福利部中央健康保險署. 2017-02-06  [2017-04-10]. （原始内容存档 (PDF)于2017-04-10）.
↑  Punja, Salima. . Cochrane Database of Systematic Reviews. 2016-02, 2: CD009996. PMID 26844979. doi:10.1002/14651858.CD009996.pub2.
1 2 3  Heal DJ, Smith SL, Gosden J, Nutt DJ. . J. Psychopharmacol. 2013-06, 27 (6): 479–496. PMC 3666194 . PMID 23539642. doi:10.1177/0269881113482532.
1 2   (PDF). United States Food and Drug Administration. Tris Pharma, Inc.: 1–14. 2017-05  [2017-08-04]. （原始内容存档 (PDF)于2020-10-18）. DYANAVEL XR contains d-amphetamine and l-amphetamine in a ratio of 3.2 to 1 ...
DOSAGE FORMS AND STRENGTHS
Extended-release oral suspension contains 2.5 mg amphetamine base per mL.
↑   (PDF). Arbor Pharmaceuticals LLC: 1–2. 2014-04  [2015-08-11]. （原始内容存档 (PDF)于2016-03-04）.
↑  Glaser; Thomas, TC; Joyce, BM; Castellanos, FX; Gerhardt, GA;  et al. . Psychopharmacology. 2005, 178 (2–3): 250–258 (Page: 255). PMID 15719230. doi:10.1007/s00213-004-2012-6.
↑  Schepers, RJ. . Clinical Chemistry. 2003, 49 (1): 121–132 [121, 130]. PMID 12507968. doi:10.1373/49.1.121 .
↑  Shoblock; Sullivan, EB; Maisonneuve, IM; Glick, SD;  et al. . Psychopharmacology. 2003, 165 (4): 359–369 (Page:366). PMID 12491026. doi:10.1007/s00213-002-1288-7.
↑  Markowitz, JS; Patrick, KS. . Journal of Clinical Psychopharmacology. 2008-06, 28 (3 Suppl 2): S54–61. PMID 18480678. doi:10.1097/JCP.0b013e3181733560.
↑  Heal DJ, Pierce DM. . CNS Drugs. 2006, 20 (9): 713–738 (Page:730). PMID 16953648. doi:10.2165/00023210-200620090-00002.
↑  . U.S. Food and Drug Administration.   [2009-07-12]. （原始内容存档于2009-07-09）.
↑   (PDF). Eli Lilly and Company. 2014-02  [2014-09-06]. （原始内容存档 (PDF)于2014-07-09）.
↑  . FDA Center for Drug Evaluation and Research. 2007-02-22. （原始内容存档于2009-05-11）.
↑  Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, Winner PK, Dunn DW,  et al. . Neurology. 2005-12, 65 (12): 1941–9. PMID 16380617. doi:10.1212/01.wnl.0000188869.58300.a7.
↑  Arnsten AF. . Expert Rev Neurother. 2010, 10 (10): 1595–605. PMC 3143019 . PMID 20925474. doi:10.1586/ern.10.133.
↑  Frazin, Natalie. . National Institute of Neurological Disorders and Stroke. 2002-04-02  [2007-04-15]. （原始内容存档于2007-04-27）.
1 2  Lakhan, SE; Hagger-Johnson, G. . Clinical Practice and Epidemiology in Mental Health. 2007-10-20, 3 (1): 21. PMC 2100041 . PMID 17949504. doi:10.1186/1745-0179-3-21.
↑   (PDF).   [2020-01-14]. （原始内容存档 (PDF)于2013-06-08）.  (170 KB). GlaxoSmithKline (2006-09). Retrieved 2007-04-15.
↑  Stahl S, Pradko J, Haight B, Modell J, Rockett C, Learned-Coughlin S. . Prim Care Companion J Clin Psychiatry. 2004, 6 (4): 159–166. PMC 514842 . PMID 15361919. doi:10.4088/PCC.v06n0403.
↑  Biederman J, Swanson JM, Wigal SB, Boellner SW, Earl CQ, Lopez FA. . The Journal of Clinical Psychiatry. 2006-05, 67 (5): 727–35. PMID 16841622. doi:10.4088/JCP.v67n0506.
↑  Greenhill LL, Biederman J, Boellner SW. . Journal of the American Academy of Child and Adolescent Psychiatry. 2006-05, 45 (5): 503–11. PMID 16601402. doi:10.1097/01.chi.0000205709.63571.c9.
↑  Cephalon, Inc. . healthlinks.net. healthlinks.net Pty. Ltd. 2007-12-21  [2008-07-02]. （原始内容 (PDF)存档于2008-07-21）.
↑  Kumar, R. . Drugs. 2008, 68 (13): 1803–39. PMID 18729534. doi:10.2165/00003495-200868130-00003.
↑  Name, LM; Gameroff, M; Marcus, MJ; Jensen, SC; Jensen, PS. . American Journal of Psychiatry. 2003, 160 (6): 1071–1077. PMID 12777264. doi:10.1176/appi.ajp.160.6.1071.
1 2 3  Visser, SN; Danielson, ML; Bitsko, RH; Holbrook, JR; Kogan, MD; Ghandour, RM; Perou, R; Blumberg, SJ. . Journal of the American Academy of Child and Adolescent Psychiatry. 2014-01, 53 (1): 34–46.e2. PMC 4473855 . PMID 24342384. doi:10.1016/j.jaac.2013.09.001.
↑  . Centers for Disease Control and Prevention. 2013-11-13  [2014-09-06]. （原始内容存档于2019-05-31）.
↑  Singh, Ilina.  (PDF). Nature Reviews Neuroscience. 2008, 9 (12): 957–964  [2020-01-22]. PMID 19020513. doi:10.1038/nrn2514. （原始内容存档 (PDF)于2020-01-31）.
1 2  Greenhill, L.; Kollins, S.; Abikoff, H.; McCracken, J.; Riddle, M.; Swanson, J.; McGough, J.; Wigal, S.;  et al. . J Am Acad Child Adolesc Psychiatry. 2006-11, 45 (11): 1284–93. PMID 17023867. doi:10.1097/01.chi.0000235077.32661.61.
↑  Freudenheim, Milt. . The New York Times. 2004-05-17  [2010-04-25].
↑  . ConsumerAffairs. Consumers Unified LLC. 2006-10-24  [2013-10-26]. （原始内容存档于2018-12-12）.
↑  Chung, Jaeah. . 2013  [2013-10-26]. （原始内容存档于2013-05-28）.
↑  Manos, Michael J. . Medscape Psychiatry. 2006, 11 (1)  [2020-01-22]. （原始内容存档于2017-06-21）.
1 2  Cortese, S; Holtmann, M; Banaschewski, T; Buitelaar, J; Coghill, D; Danckaerts, M; Dittmann, RW; Graham, J; Taylor, E; Sergeant, J; European ADHD Guidelines, Group. . Journal of Child Psychology and Psychiatry, and Allied Disciplines. 2013-03, 54 (3): 227–46. PMID 23294014. doi:10.1111/jcpp.12036.
↑  Bhandari, Smitha. . WebMD. WebMD.   [2015-10-16]. （原始内容存档于2019-03-31）.
↑  Gelperin, Kate.  (PDF). Food and Drug Administration (US). 2006-02-09  [2020-01-25]. （原始内容存档 (PDF)于2017-08-30）.
↑  Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA. . N. Engl. J. Med. 2011-11, 365 (20): 1896–1904. PMC 4943074 . PMID 22043968. doi:10.1056/NEJMoa1110212.
↑  . United States Food and Drug Administration. 2011-12-15  [2013-11-04]. （原始内容存档于2013-10-30）.
↑  Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV. . JAMA. 2011-12, 306 (24): 2673–2683. PMC 3350308 . PMID 22161946. doi:10.1001/jama.2011.1830.
↑  . United States Food and Drug Administration. 2011-12-20  [2013-11-04]. （原始内容存档于2013-10-30）.
↑   (PDF). Food and Drug Administration (US). 2006  [2020-01-29]. （原始内容存档 (PDF)于2017-05-10）.
↑  Silver, Larry. . ADDitude magazine. New Hope Media LLC. 2006-02  [2020-01-29]. （原始内容存档于2016-12-21）.
↑  Kraemer M, Uekermann J, Wiltfang J, Kis B. . Clin Neuropharmacol. 2010-07, 33 (4): 204–6. PMID 20571380. doi:10.1097/WNF.0b013e3181e29174.
↑  Wingo, AP; Ghaemi, SN. . Psychopharmacology Bulletin. 2008, 41 (4): 37–47. PMID 19015628.
↑  Kimko HC, Cross JT, Abernethy DR. . Clin Pharmacokinet. 1999-12, 37 (6): 457–70. PMID 10628897. doi:10.2165/00003088-199937060-00002.
↑  Mosholder, Andrew D.; Gelperin, Kate. . Pediatrics. 2009-02-01, 123 (2): 611–616  [2013-10-23]. PMID 19171629. doi:10.1542/peds.2008-0185. （原始内容存档于2021-04-11）.
↑  Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, Bastos Mde L. . Arch. Toxicol. August 2012, 86 (8): 1167–1231. PMID 22392347. doi:10.1007/s00204-012-0815-5.
↑  Berman S, O'Neill J, Fears S, Bartzokis G, London ED. . Ann. N. Y. Acad. Sci. 2008, 1141 (1): 195–220. Bibcode:2008NYASA1141..195B. PMC 2769923 . PMID 18991959. doi:10.1196/annals.1441.031.
1 2  Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K. . JAMA Psychiatry. February 2013, 70 (2): 185–198. PMID 23247506. doi:10.1001/jamapsychiatry.2013.277.
1 2  Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, Faraone SV, Biederman J. . J. Clin. Psychiatry. September 2013, 74 (9): 902–917. PMC 3801446 . PMID 24107764. doi:10.4088/JCP.12r08287.
1 2  Frodl T, Skokauskas N. . Acta Psychiatrica Scand. February 2012, 125 (2): 114–126. PMID 22118249. doi:10.1111/j.1600-0447.2011.01786.x. Basal ganglia regions like the right globus pallidus, the right putamen, and the nucleus caudatus are structurally affected in children with ADHD. These changes and alterations in limbic regions like ACC and amygdala are more pronounced in non-treated populations and seem to diminish over time from child to adulthood. Treatment seems to have positive effects on brain structure.
↑  Millichap JG. . Millichap JG  (编).  2nd. New York: Springer. 2010: 111–113. ISBN 978-1-4419-1396-8.
1 2  Huang YS, Tsai MH. . CNS Drugs. July 2011, 25 (7): 539–554. PMID 21699268. doi:10.2165/11589380-000000000-00000.
1 2  Millichap JG. . Millichap JG  (编).  2nd. New York: Springer. 2010: 121–123. ISBN 978-1-4419-1396-8.
↑  Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. . Am J Psychiatry. March 2012, 169 (3): 264–72. PMID 22294258. doi:10.1176/appi.ajp.2011.11060940.
↑  Kooij, SJ.; Bejerot, S.; Blackwell, A.; Caci, H.; Casas-Brugué, M.; Carpentier, PJ.; Edvinsson, D.; Fayyad, J.;  et al. . BMC Psychiatry. 2010, 10: 67. PMC 2942810 . PMID 20815868. doi:10.1186/1471-244X-10-67.
↑  Brown, TE. . Curr Psychiatry Rep. October 2008, 10 (5): 407–11. PMID 18803914. doi:10.1007/s11920-008-0065-7.
↑  Garland EJ. . J. Psychopharmacol. (Oxford). 1998, 12 (4): 385–95. PMID 10065914. doi:10.1177/026988119801200410.
↑  Nolan EE, Gadow KD, Sprafkin J. . Pediatrics. April 1999, 103 (4 Pt 1): 730–7. PMID 10103294. doi:10.1542/peds.103.4.730.
↑  Ackerman, Todd. . Houston Chronicle. 2005-07-01  [2011-07-10]. （原始内容存档于2022-08-22）.
↑  Walitza, Susanne;  et al. . Environmental Health Perspectives. 2007-06, 115 (6): 936–940. PMC 1892117 . PMID 17589603. doi:10.1289/ehp.9866.
1 2 3 4  Lange, KW.; Reichl, S.; Lange, KM.; Tucha, L.; Tucha, O. . Atten Defic Hyperact Disord. December 2010, 2 (4): 241–55. PMC 3000907 . PMID 21258430. doi:10.1007/s12402-010-0045-8.
↑  Brown, Walter A. . American Journal of Psychiatry. July 1998, 155 (7): 968. doi:10.1176/ajp.155.7.968 .
↑   (PDF). FDA.   [2019-05-22]. （原始内容存档 (PDF)于2017-02-11）.
↑   (PDF). FDA.   [2019-05-22]. （原始内容存档 (PDF)于2021-04-03）.
↑  . FDA.   [2019-05-22]. （原始内容存档于2012-09-02）.
↑  . Stamford Advocate（英语：）. 2019-04-07  [2019-05-22]. （原始内容存档于2019-05-28）.
↑  Schlander. . European Child & Adolescent Psychiatry. 2007, 16 (7): 421–429 (Page:421). PMID 17401606. doi:10.1007/s00787-007-0615-2.  的存檔，存档日期14 October 2007.
↑  Bader, A; Adesman, A. . Current Opinion in Pediatrics. December 2012, 24 (6): 760–9. PMID 23111680. doi:10.1097/mop.0b013e32835a1a5f.
1 2  Sonuga-Barke, EJ; Brandeis, D; Cortese, S; Daley, D; Ferrin, M; Holtmann, M; Stevenson, J; Danckaerts, M; van der Oord, S; Döpfner, M; Dittmann, RW; Simonoff, E; Zuddas, A; Banaschewski, T; Buitelaar, J; Coghill, D; Hollis, C; Konofal, E; Lecendreux, M; Wong, IC; Sergeant, J; European ADHD Guidelines, Group. . The American Journal of Psychiatry. 2013-03-01, 170 (3): 275–89. PMID 23360949. doi:10.1176/appi.ajp.2012.12070991.
↑  Greydanus, DE; Pratt, HD; Patel, DR. . Disease-a-month. February 2007, 53 (2): 70–131. PMID 17386306. doi:10.1016/j.disamonth.2007.01.001.
1 2 3  Moriyama TS, Polanczyk G, Caye A, Banaschewski T, Brandeis D, Rohde LA. . Neurotherapeutics. July 2012, 9 (3): 588–98. PMC 3441929 . PMID 22930416. doi:10.1007/s13311-012-0136-7.
↑  Lofthouse N, Arnold LE, Hurt E. . Curr Psychiatry Rep. October 2012, 14 (5): 536–42. PMID 22890816. doi:10.1007/s11920-012-0301-z.
↑  Holtmann, M; Sonuga-Barke, E; Cortese, S; Brandeis, D. . Child and Adolescent Psychiatric Clinics of North America. October 2014, 23 (4): 789–806  [2019-12-23]. PMID 25220087. doi:10.1016/j.chc.2014.05.006. hdl:1854/LU-5841198. （原始内容存档于2021-01-17）.
↑  Author:Graham A Colditz, MD, DrPH; Section Editor:David Seres, MD; Deputy Editor:Lisa Kunins, MD. . UpToDate.   [2019-08-23]. （原始内容存档于2021-04-08）.
↑  Author:Graham A Colditz, MD, DrPH; Section Editor:David Seres, MD; Deputy Editor:Lisa Kunins, MD. . UpToDate.   [2019-08-23]. （原始内容存档于2019-07-01）.
↑  The doctors and editors at UpToDate. . UpToDate.   [2019-08-23]. （原始内容存档于2019-08-23）.
↑  Wolraich, Mark L. . JAMA (American Medical Association (AMA)). 1995-11-22, 274 (20): 1617. ISSN 0098-7484. doi:10.1001/jama.1995.03530200053037. The meta-analytic synthesis of the studies to date found that sugar does not affect the behavior or cognitive performance of children. The strong belief of parents may be due to expectancy and common association. However, a small effect of sugar or effects on subsets of children cannot be ruled out.(JAMA. 1995;274:1617-1621)
↑  American Academy of Pediatrics. . HealthyChildren.org. 2018-07-13  [2018-07-13]. （原始内容存档于2017-12-21）.
↑  Dietz, William. . Elk Grove Village, IL: American Academy of Pediatrics. 2012. ISBN 978-1-58110-631-2. OCLC 767736204.
↑  Nigg JT, Lewis K, Edinger T, Falk M. . J Am Acad Child Adolesc Psychiatry. January 2012, 51 (1): 86–97. PMID 22176942. doi:10.1016/j.jaac.2011.10.015.
1 2 3 4  Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, Stevenson J, Danckaerts M, van der Oord S, Döpfner M, Dittmann RW, Simonoff E, Zuddas A, Banaschewski T, Buitelaar J, Coghill D, Hollis C, Konofal E, Lecendreux M, Wong IC, Sergeant J. . Am J Psychiatry. 2013-03, 170 (3): 275–289. PMID 23360949. doi:10.1176/appi.ajp.2012.12070991. Free fatty acid supplementation and artificial food color exclusions appear to have beneficial effects on ADHD symptoms, although the effect of the former are small and those of the latter may be limited to ADHD patients with food sensitivities...
1 2  Nigg JT, Holton K. . Child Adolesc Psychiatr Clin N Am (Review). 2014-10, 23 (4): 937–53. PMC 4322780 . PMID 25220094. doi:10.1016/j.chc.2014.05.010. an elimination diet produces a small aggregate effect but may have greater benefit among some children. Very few studies enable proper evaluation of the likelihood of response in children with ADHD who are not already preselected based on prior diet response.
↑  Ertürk, E; Wouters, S; Imeraj, L; Lampo, A. . Journal of Attention Disorders (Review). 2016-01-29. PMID 26825336. doi:10.1177/1087054715611493.
↑  Konikowska K, Regulska-Ilow B, Rózańska D. . Rocz Panstw Zakl Hig. 2012, 63 (2): 127–134. PMID 22928358.